• 1. Excimer formation effects and trap-assisted charge recombination loss channels in organic solar cells of perylene diimide dimer acceptors?
  Min Kim,Jae-Joon Lee,Tengling Ye,Panagiotis E. Keivanidis,Kilwon Cho J. Mater. Chem. C, 2020,8, 1686-1696
• 2. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
• 3. Emulsion soft templating of carbide-derived carbon nanospheres with controllable porosity for capacitive electrochemical energy storage?
  M. Zeiger,N. J?ckel,P. Strubel,L. Borchardt,R. Reinhold,W. Nickel,J. Eckert,V. Presser,S. Kaskel J. Mater. Chem. A, 2015,3, 17983-17990
• 4. Fc microparticles can modulate the physical extent and magnitude of complement activity?
  David White,Sean R. Stowell Biomater. Sci., 2017,5, 463-474
• 5. Enabling high-throughput single-animal gene-expression studies with molecular and micro-scale technologies
  Jason Wan Lab Chip, 2020,20, 4528-4538

Introduction to 6-fluoro-2,3-dihydro-1,2-benzothiazol-3-one (CAS No. 159803-11-9)

6-fluoro-2,3-dihydro-1,2-benzothiazol-3-one, identified by its CAS number 159803-11-9, is a heterocyclic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research. This compound belongs to the benzothiazole class, a scaffold widely recognized for its biological activity and structural versatility. The presence of a fluorine atom at the 6-position enhances its pharmacological properties, making it a valuable candidate for further investigation in drug discovery.

The benzothiazole core is a prominent motif in many bioactive molecules, exhibiting a broad spectrum of pharmacological effects including antimicrobial, anti-inflammatory, and anticancer activities. The addition of a fluorine substituent at the 6-position of the benzothiazole ring can modulate the electronic properties of the molecule, potentially influencing its binding affinity and metabolic stability. This modification has been strategically employed in the development of novel therapeutic agents to improve their efficacy and pharmacokinetic profiles.

In recent years, there has been a surge in research focused on the synthesis and characterization of fluorinated benzothiazole derivatives. These compounds have shown promise in various preclinical studies, highlighting their potential as lead compounds for the development of new drugs. The fluorine atom can participate in multiple non-covalent interactions with biological targets, such as hydrogen bonding and π-stacking, which can enhance the binding affinity and selectivity of the molecule.

The synthesis of 6-fluoro-2,3-dihydro-1,2-benzothiazol-3-one involves multi-step organic transformations that require precise control over reaction conditions to ensure high yield and purity. Advanced synthetic methodologies, including transition metal-catalyzed reactions and asymmetric synthesis techniques, have been employed to construct the desired molecular framework efficiently. The introduction of fluorine into the benzothiazole ring often necessitates specialized reagents and catalysts to achieve optimal results.

The biological activity of 6-fluoro-2,3-dihydro-1,2-benzothiazol-3-one has been extensively studied in various in vitro and in vivo models. Preliminary findings suggest that this compound exhibits potent inhibitory effects on certain enzymes and receptors implicated in diseases such as cancer and inflammation. The fluorine substituent appears to play a crucial role in modulating these interactions, thereby enhancing the therapeutic potential of the molecule.

One of the most compelling aspects of this compound is its potential to serve as a scaffold for structure-based drug design. By leveraging computational modeling techniques such as molecular docking and molecular dynamics simulations, researchers can gain insights into the binding mechanisms of 6-fluoro-2,3-dihydro-1,2-benzothiazol-3-one with biological targets. This information can be used to optimize the compound's structure further, leading to more effective and selective therapeutic agents.

The pharmaceutical industry has shown great interest in fluorinated heterocycles due to their favorable pharmacokinetic properties. Fluorine atoms can influence metabolic stability by preventing rapid degradation by enzymes such as cytochrome P450 oxidases. Additionally, fluorine substitution can enhance lipophilicity, improving drug absorption and distribution throughout the body. These attributes make 6-fluoro-2,3-dihydro-1,2-benzothiazol-3-one an attractive candidate for further development.

In conclusion, 6-fluoro-2,3-dihydro-1,2-benzothiazol-3-one (CAS No. 159803-11-9) represents a promising compound in the realm of pharmaceutical research. Its unique structural features and demonstrated biological activity position it as a valuable asset for drug discovery efforts aimed at addressing various therapeutic challenges. As research continues to uncover new applications for this compound, it is likely to play an increasingly important role in the development of next-generation pharmaceuticals.

• 15913-48-1(1,2-Benzisothiazol-3(2H)-one, 4-methyl-)
• 4337-46-6(1,2-BENZISOTHIAZOL-3(2H)-ONE, 5-METHYL-)
• 114378-36-8(1,2-Benzisothiazol-2(3H)-yl, 3-oxo-)
• 4337-47-7(6-methyl-2,3-dihydro-1,2-benzothiazol-3-one)
• 18336-03-3(5-Butyl-1,2-benzothiazol-3(2H)-one)
• 1329616-16-1(Benzoisothiazol-3-one-13C6)
• 159803-10-8(5-fluoro-2,3-dihydro-1,2-benzothiazol-3-one)
• 38521-29-8(1,2-benzisothiazol-3(2H)-one, compound with ethane-1,2-diamine)
• 2634-33-5(Benzoisothiazol-3-one)
• 58249-25-5(1,2-Benzoisothiazolin-3-one, sodium salt)